MGC Pharmaceuticals well positioned to benefit from UN’s decision to reclassify cannabis as less dangerous drug

The company’s flagship phytomedicines will now have far fewer obstacles to overcome as they work towards market authorisation, registration and patient access. () () (FRA:H5O) is expected to benefit from the United Nations’ (UN) decision to remove cannabis and its derivatives from schedule IV following recommendations from the World Health ... Read More